NMT Medical starts US trial for PFO(patent foramen ovale)/migraine therapy STARFlex implant:
This article was originally published in Clinica
Executive Summary
NMT Medical has begun a US trial to test its heart repair implant as a treatment for migraine headaches. The MIST II trial, which has begun patient enrolment, will assess the firm's STARFlex device, which is used to close a patent foramen ovale (PFO), a cardiac defect that has been linked an increased risk of migraine, recurrent stroke and transient ischaemic attacks. It will involve 600 patients, with enrolment scheduled for completion by the end of this year. Patients will be followed-up over a one-year period. The Boston, Massachusetts firm has already completed enrolment in a UK PFO/migraine study, MIST, results from which are scheduled for release in late March or early April 2006.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.